Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 22, 2007 Brian Lawler	No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
The Motley Fool April 21, 2005 Stephen D. Simpson	Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space.
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool April 22, 2008 Brian Lawler	No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool January 29, 2009 Brian Orelli	Novartis: Diversification Isn't Good Enough Novartis has become a better diversified company, with acquisitions of vaccines specialist Chiron and 25% of eye-care specialist Alcon, but it's far from a cure all, as the fourth quarter showed.
The Motley Fool October 21, 2008 Brian Orelli	Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant.
The Motley Fool April 25, 2007 Brian Lawler	Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note.
The Motley Fool September 20, 2005 Brian Gorman	Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
The Motley Fool April 24, 2006 Stephen D. Simpson	Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions.
The Motley Fool June 6, 2008 Brian Lawler	Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them.
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
The Motley Fool July 17, 2006 Stephen D. Simpson	Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
The Motley Fool October 30, 2006 Brian Lawler	Reddy, Set, Go for Earnings Growth With margins tightening, generic drug maker Dr. Reddy's Laboratories finds an Rx for success. Investors, take note.
The Motley Fool March 16, 2005 Cliff Malings	Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition.
The Motley Fool July 28, 2011 Melly Alazraki	J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.
The Motley Fool October 18, 2005 Stephen D. Simpson	More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool July 17, 2007 Brian Lawler	Still Strong at Novartis For investors who are willing to filter the negative news and are patient enough to wait for recently launched branded compounds to help its top-line growth, Novartis is worth a look
The Motley Fool July 15, 2005 Stephen D. Simpson	Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
Pharmaceutical Executive November 1, 2006 Joanna Breitstein	Back Page: The Case for Diversity Variety is the spice of life - and the future of Big Pharma.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool June 7, 2004 Brian Gorman	Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool April 8, 2008 Brian Lawler	Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history.
The Motley Fool January 27, 2010 Brian Orelli	Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool November 6, 2006 Brian Lawler	The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note.
The Motley Fool September 1, 2005 Stephen D. Simpson	Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note.
The Motley Fool August 17, 2009 Brian Orelli	Preparing for a Home Run Some good news and bad news for companies selling drugs to treat multiple sclerosis, after Novartis announces Extavia has been approved by the FDA.
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool April 14, 2005 Brian Gorman	Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
Pharmaceutical Executive November 1, 2008	No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?
The Motley Fool September 21, 2005 Rich Duprey	A Shot of Reality for Chiron Novartis warns pharma it's willing to walk away from takeover bid. Does Chiron have the wherewithal to go it alone? Investors, take note.